ANIP ANI Pharmaceuticals, Inc.
Legal ·
A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.
Orphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium.
ANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding.
ANI Pharmaceuticals describes itself as a diversified biopharmaceutical company that develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Brands businesses. On September 16, 2024, it acquired Alimera Sciences, adding two products, ILUVIEN and YUTIQ. In March 2025 the FDA approved an expanded ILUVIEN label to include chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to diabetic macular edema (DME). The company is marketing ILUVIEN for both indications in the U.S. In the second quarter of 2025 it moved its U.S. promotional efforts from YUTIQ to ILUVIEN. ILUVIEN was already approved for both indications outside the U.S., including in seventeen European countries. ANI owns and operates three pharmaceutical manufacturing facilities, two in Baudette, Minnesota and one in East Windsor, New Jersey, which can produce oral solid dose products, semi-solids, liquids, topicals, controlled substances and potent products. It ceased operations at a facility in Oakville, Ontario as of March 31, 2023.
| Product or program | What it is | Stage |
|---|---|---|
| ILUVIEN | Eye product for diabetic macular edema and posterior segment uveitis | approved |
| YUTIQ | Eye product added through the Alimera acquisition |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $51.7 million | $44.6 million |
| Net income (loss) | $78.3 million | -$18.5 million |
| Cash from operations | $185.2 million | $64.0 million |
| Cash and equivalents | $285.6 million | $144.9 million |
Our latest story on this, dated Aug 7, 2026: "ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third". The story links the filing or release it is based on. Read the story.
ANI Pharmaceuticals, Inc. trades under the ticker ANIP on NASDAQ.
ANI Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:BSFA; LS:A1W15D; LSX:A1W15D.
The SEC Central Index Key (CIK) for ANI Pharmaceuticals, Inc. is 1023024. Its filings are on SEC EDGAR.
24,422,240 shares as of 2013-02-28, per the cover page of its 10-K filed 2013-02-28.
Our directory records ANI Pharmaceuticals, Inc. under United States.
Our directory classifies ANI Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ANI Pharmaceuticals, Inc. is US00182C1036.
aibio.space lists ANI Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
ANI Pharmaceuticals describes itself as a diversified biopharmaceutical company that develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Brands businesses. On September 16, 2024, it acquired Alimera Sciences, adding two products, ILUVIEN and YUTIQ.
ILUVIEN: Eye product for diabetic macular edema and posterior segment uveitis Stage: approved.
YUTIQ: Eye product added through the Alimera acquisition
ANI Pharmaceuticals, Inc. reported net income of $78.3 million for the fiscal year ended Dec 31, 2025, and generated $185.2 million of cash from operations, per its annual report to the SEC.
$51.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio